このページの翻訳は実験的なもので、現在開発中です。お待ちしております

Rigel Pharmaceuticals 将来の成長

Future 基準チェック /56

Rigel Pharmaceuticals利益と収益がそれぞれ年間57.8%と15.7%増加すると予測されています。EPS は年間増加すると予想されています。自己資本利益率は 3 年後に1022.1% 59%なると予測されています。

主要情報

57.8%

収益成長率

59.0%

EPS成長率

Biotechs 収益成長	28.4%
収益成長率	15.7%
将来の株主資本利益率	1,022.1%
アナリストカバレッジ	Good
最終更新日	07 Aug 2024

今後の成長に関する最新情報

Recent updates

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Shares Fly 31% But Investors Aren't Buying For Growth

Sep 25

There's No Escaping Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) Muted Revenues Despite A 29% Share Price Rise

Jul 30

Rigel Pharmaceuticals: Undervalued FDA-Approved Products With Promising Cash Flow Potential

Jul 24

Little Excitement Around Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) Revenues As Shares Take 29% Pounding

May 01

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Mar 08

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Surges 36% Yet Its Low P/S Is No Reason For Excitement

Mar 04

Rigel Pharmaceuticals: Upgrading To A 'Top Idea' Ahead Of Promising Q4/2023 Earnings Report

Feb 23

Lacklustre Performance Is Driving Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) Low P/S

Jan 15

What Does The Future Hold For Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL)? These Analysts Have Been Cutting Their Estimates

Mar 06

Rigel PharmaceuticalsA Biopharma With A Free Shot On Goal In COVID-19, With A Pipeline As A Safety Net

Feb 01

An Intrinsic Calculation For Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Suggests It's 26% Undervalued

Jan 14

業績と収益の成長予測

NasdaqGS:RIGL - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	229	32	42	N/A	6
12/31/2025	195	12	20	N/A	6
12/31/2024	155	-5	N/A	N/A	6
6/30/2024	130	-14	-13	-12	N/A
3/31/2024	119	-20	-7	-7	N/A
12/31/2023	116	-25	-21	-6	N/A
9/30/2023	129	-24	-36	-21	N/A
6/30/2023	121	-38	-49	-33	N/A
3/31/2023	125	-45	-67	-52	N/A
12/31/2022	116	-59	-74	-74	N/A
9/30/2022	86	-83	-71	-71	N/A
6/30/2022	87	-85	-68	-68	N/A
3/31/2022	77	-85	-1	0	N/A
12/31/2021	139	-18	5	6	N/A
9/30/2021	138	-15	8	9	N/A
6/30/2021	136	-8	-1	0	N/A
3/31/2021	131	-11	-70	-69	N/A
12/31/2020	109	-30	-53	-52	N/A
9/30/2020	106	-28	-48	-46	N/A
6/30/2020	108	-25	-43	-41	N/A
3/31/2020	102	-28	-46	-44	N/A
12/31/2019	59	-67	-43	-42	N/A
9/30/2019	82	-46	-21	-20	N/A
6/30/2019	66	-59	-26	-26	N/A
3/31/2019	57	-64	-37	-36	N/A
12/31/2018	45	-70	-60	-59	N/A
9/30/2018	7	-100	-91	-90	N/A
6/30/2018	3	-93	-89	-88	N/A
3/31/2018	1	-87	N/A	-80	N/A
12/31/2017	4	-78	N/A	-78	N/A
9/30/2017	7	-68	N/A	-70	N/A
6/30/2017	10	-73	N/A	-75	N/A
3/31/2017	19	-67	N/A	-74	N/A
12/31/2016	20	-69	N/A	-76	N/A
9/30/2016	26	-66	N/A	-77	N/A
6/30/2016	35	-50	N/A	-64	N/A
3/31/2016	32	-51	N/A	-64	N/A
12/31/2015	29	-51	N/A	-23	N/A
9/30/2015	29	-61	N/A	-25	N/A
6/30/2015	16	-75	N/A	-34	N/A
3/31/2015	10	-87	N/A	-35	N/A
12/31/2014	8	-91	N/A	-70	N/A
9/30/2014	6	-85	N/A	-74	N/A
6/30/2014	6	-88	N/A	-76	N/A
3/31/2014	7	-86	N/A	-77	N/A
12/31/2013	7	-89	N/A	-86	N/A
9/30/2013	1	-98	N/A	-89	N/A

アナリストによる今後の成長予測

収入対貯蓄率: RIGLは今後 3 年間で収益性が向上すると予測されており、これは貯蓄率 ( 2.5% ) よりも高い成長率であると考えられます。

収益対市場: RIGL今後 3 年間で収益性が向上すると予想されており、これは市場平均を上回る成長と考えられます。

高成長収益: RIGL今後 3 年以内に収益を上げることが予想されます。

収益対市場: RIGLの収益 ( 17.4% ) US市場 ( 8.7% ) よりも速いペースで成長すると予測されています。

高い収益成長: RIGLの収益 ( 15.7% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: RIGLの自己資本利益率は、3年後には非常に高くなると予測されています ( 125.5 %)。

Rigel Pharmaceuticals 将来の成長

Future 基準チェック /56

主要情報

今後の成長に関する最新情報

Price target increased by 34% to US$26.75

Forecast breakeven date moved forward to 2024

Consensus EPS estimates upgraded to US$0.43 loss

Price target increased by 44% to US$65.33

Consensus EPS estimates upgraded to US$0.65 loss

Consensus EPS estimates upgraded to US$0.062 loss

Recent updates

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Shares Fly 31% But Investors Aren't Buying For Growth

Rigel Announces First Patient Enrolled in Phase 1b/2 Triplet Therapy Trial of REZLIDHIA® (olutasidenib) in mIDH1 AML

Price target increased by 34% to US$26.75

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Forecast breakeven date moved forward to 2024

There's No Escaping Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) Muted Revenues Despite A 29% Share Price Rise

Rigel Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 06, 2024

Consensus EPS estimates upgraded to US$0.43 loss

Rigel Pharmaceuticals: Undervalued FDA-Approved Products With Promising Cash Flow Potential

Price target increased by 44% to US$65.33

Consensus EPS estimates upgraded to US$0.65 loss

Rigel Pharmaceuticals Completes Transfer of GAVRETO®? (pralsetinib) New Drug Application

Rigel Pharmaceuticals, Inc. Announces Five Presentations at the EHA2024 Hybrid Congress

Insufficient new directors

Consensus EPS estimates upgraded to US$0.062 loss

Consensus EPS estimates upgraded to US$0.073 loss

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Little Excitement Around Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) Revenues As Shares Take 29% Pounding

Rigel Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 07, 2024

Price target increased by 14% to US$5.08

Rigel Pharmaceuticals, Inc., Annual General Meeting, May 22, 2024

Consensus EPS estimates fall by 13%

Rigel Pharmaceuticals Announces Appointment of Lisa Rojkjaer as Chief Medical Officer

Consensus estimates of losses per share improve by 12%

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Forecast breakeven date moved forward to 2025

Price target increased by 10% to US$4.46

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Surges 36% Yet Its Low P/S Is No Reason For Excitement

Rigel Pharmaceuticals, Inc. to Report Q4, 2023 Results on Mar 05, 2024

Rigel Pharmaceuticals: Upgrading To A 'Top Idea' Ahead Of Promising Q4/2023 Earnings Report

President recently sold US$60k worth of stock

Lacklustre Performance Is Driving Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) Low P/S

No longer forecast to breakeven

New minor risk - Share price stability

Forecast to breakeven in 2025

Rigel Pharmaceuticals, Inc. Receives A Deficiency Letter from the Listing Qualifications Department of the Nasdaq Stock Market LLC

Consensus EPS estimates upgraded to US$0.19 loss

Forecast to breakeven in 2025

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Rigel Pharmaceuticals, Inc. Announces Poster Presentations At the 65Th American Society of Hematology Annual Meeting and Exposition

Rigel Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Rigel Pharmaceuticals, Inc. Announces Presentation of Data from the Focus Phase 3 Clinical Trial of Fostamatinib in Hospitalized COVID-19 Patients and Provides Update on ACTIV-4 Host Tissue Trial

Consensus EPS estimates upgraded to US$0.25 loss

New minor risk - Profitability

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Rigel Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 01, 2023

Rigel Pharmaceuticals, Inc. Announces Presentation of Data from Analysis of REZLIDHIA® (Olutasidenib) in Post-Venetoclax Patients with Mutant IDH1 AML

Rigel Pharmaceuticals, Inc. Announces Second -2-2-Appointment of Olutasidenib as Therapeutics

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Forecast to breakeven in 2025

Price target increased by 7.6% to US$3.85

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Rigel Pharmaceuticals, Inc. Announces Resignation of Wolfgang Dummer as Executive Vice President and Chief Medical Officer, Effective March 31, 2023

Rigel Pharmaceuticals, Inc. Announces Publication of REZLIDHIA (Olutasidenib) Phase 2 Clinical Results in Blood Advances

National Comprehensive Cancer Network Adds Newly Approved Rigel Pharmaceuticals, Inc.'s REZLIDHIA™ (Olutasidenib) to Clinical Practice Guidelines in Oncology for Acute Myeloid Leukemia

Price target increased to US$4.11

Rigel Pharmaceuticals, Inc. Provides Revenue Guidance for the Fourth Quarter of 2022

Rigel Pharmaceuticals, Inc. Announces Availability of REZLIDHIA™ (olutasidenib) in the U.S. for the Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia with a Susceptible IDH1 Mutation

Rigel Pharmaceuticals, Inc. Doses First Patient in Phase 1b Study of R289 for the Treatment of Lower-Risk Myelodysplastic Syndromes

Rigel Pharmaceuticals, Inc. Announces U.S. FDA Approval of REZLIDHIA™ (olutasidenib) for the Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia with a Susceptible IDH1 Mutation

Rigel Pharmaceuticals Received a Deficiency Letter from the Listing Qualifications Department of the Nasdaq Stock Market

Rigel Pharmaceuticals, Inc. Announces Publication of Early Clinical Data of Olutasidenib in the Lancet Haematology

Third quarter 2022 earnings: EPS exceeds analyst expectations

Rigel Pharmaceuticals, Inc. Announces Top-Line Results from Focus Phase 3 Clinical Trial of Fostamatinib in High Risk Hospitalized Covid-19 Patients

Rigel Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Is Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Trading At A 25% Discount?

Now 22% undervalued after recent price drop

Rigel Pharmaceuticals, Inc. Provides Update on Plans for sNDA for wAIHA Program Following FDA Feedback

Rigel cutting 16% of workforce after declining to file sNDA for fostamatinib